Topic #355 - sbir phase II - a 3D perfusable platform for HTS across diverse racial/ethnic cancer SPE
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91019C00041
- Awardee
-
Mimetas US Inc. UEI QGP7JLTGMAK9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,000,000
Award facts
- Opportunity
-
- BAAN44CO8900449 Solicitation number
- Contract value 100% obligated
- $2,000,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- MONTGOMRY VLG, MD 20877, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,000,000 |
About this award
This is a $2,000,000 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Mimetas US Inc., a self-certified small disadvantaged business based in Montgomery Village, Maryland. The contract is for the development of a 3D perfusable platform for high-throughput screening (HTS) across diverse racial/ethnic cancer specimens. This system aims to enable personalized medicine approaches by evaluating cancer treatments on patient-derived tumor samples. Mimetas US Inc. has also received several other federal grants, primarily from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to support the development of advanced 3D cell culture models and organ-on-a-chip systems for disease modeling and drug discovery applications, particularly in the area of kidney diseases.
Quick answers
Who was awarded contract 75N91019C00041?
75N91019C00041 was awarded to Mimetas US Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2019.
How much is contract 75N91019C00041 worth?
The government has obligated $2,000,000 on 75N91019C00041.
Was contract 75N91019C00041 competed?
The extent of competition for 75N91019C00041 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award